Amyl Therapeutics

Amyl Therapeutics has developed a novel mechanism to conformationally bind to the amyloid fold of toxic protein aggregates of various types, causing neurodegenerative diseases or systemic amyloidosis diseases. The pan-amyloid binding and amyloid fibril remodeling capabilities of Amyl therapeutic candidates position them to be maximally effective and transforming therapeutics for amyloid-related neurodegenerative disorders.

Headquartered in Liège, Belgium, Amyl Therapeutics was founded in November 2020 by Dr. Florent Gros and Dr. Pierre Vandepapelière. The company employs six staff. Founding investors include Noshaq, Merieux Equity Partners, Smedvig Funds, Ifoghas investments, JFG Life Science Foundation, Mr. Kenneth Buckfire and 6K Venture Capital.